Hommel Inge, van Gurp Petra J, den Broeder Alfons A, Wollersheim Hub, Atsma Femke, Hulscher Marlies E J L, Tack Cees J
Radboud University Medical Center, Radboud Institute for Health Sciences, Scientific Institute for Quality of Healthcare, Nijmegen, The Netherlands.
Department of General Internal Medicine, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands.
Horm Metab Res. 2017 Jul;49(7):527-533. doi: 10.1055/s-0043-105501. Epub 2017 Apr 24.
As perioperative hyperglycemia is associated with poor postoperative patient outcomes, clinical guidelines provide recommendations for optimal perioperative glucose control. It is unclear to what extent recommended glucose levels are met in daily practice, and little is known about factors that influence these levels. We describe blood glucose levels throughout the hospital care pathway in 375 non-critically ill patients with diabetes who underwent major surgery (abdominal, cardiac, or orthopedic) in 6 hospitals, examine determinants of these levels including adherence to 9 quality indicators for optimal perioperative diabetes care, and perform qualitative interviews to identify barriers for optimal care. Virtually all patients (95%) experienced at least one hyperglycemic value (>10 mmol/l); 9% had at least one value <4 mmol/l. Mean glucose increased from preoperative to postoperative day (POD) 1 (+2.3 mmol/l, 5-95% CI 1.9-2.7), and then gradually decreased on POD 2-14 (+1.8 mmol/l, 5-95% CI 1.4-2.2). Insulin-treated patients (with or without oral agents) had higher glucose levels (+1.7 mmol/l, 5-95% CI 0.5-3.0, and +1.2 mmol/l, -0.1 to -2.5) than patients using oral agents only. Indicator adherence tended to be associated with higher glucose levels. Barriers for optimal care included a lack of formalized agreements on target glucose levels, absence of directly obvious disadvantages of hyperglycemia, and concern about inducing hypoglycemia. Hyperglycemia is common after major surgery, in particular on POD1 and in insulin-treated patients. Our results suggest that perioperative diabetes care is reactive rather than proactive, and that current emphasis of professionals is on treating instead of preventing postoperative hyperglycemia.
由于围手术期高血糖与术后患者不良预后相关,临床指南针对围手术期血糖的最佳控制给出了建议。目前尚不清楚在日常实践中推荐的血糖水平在多大程度上能够得以实现,对于影响这些血糖水平的因素也知之甚少。我们描述了6家医院中375例接受大手术(腹部、心脏或骨科)的非危重症糖尿病患者在整个住院治疗过程中的血糖水平,研究了这些血糖水平的决定因素,包括对围手术期糖尿病最佳治疗9项质量指标的依从性,并进行了定性访谈以确定最佳治疗的障碍。几乎所有患者(95%)都经历过至少一次血糖值高于正常水平(>10 mmol/L);9%的患者至少有一次血糖值低于4 mmol/L。平均血糖水平从术前到术后第1天升高(+2.3 mmol/L,5-95%可信区间1.9-2.7),然后在术后第2-第14天逐渐下降(+1.8 mmol/L,5-95%可信区间1.4-2.2)。接受胰岛素治疗的患者(无论是否同时服用口服降糖药)的血糖水平高于仅服用口服降糖药的患者(分别为+1.7 mmol/L,5-95%可信区间0.5-3.0,以及+1.2 mmol/L,-0.1至-2.5)。指标依从性往往与较高的血糖水平相关。最佳治疗的障碍包括缺乏关于目标血糖水平的正式协议、高血糖没有直接明显的不良后果以及对低血糖发生的担忧。大手术后高血糖很常见,尤其是在术后第1天以及接受胰岛素治疗的患者中。我们的结果表明,围手术期糖尿病治疗是被动反应而非主动预防,并且目前专业人员的重点是治疗而非预防术后高血糖。